PPA-037 (TFA)

• Description:

  PPA-037 TFA is an orally active, highly potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12) . PPA-037 TFA induces the degradation of cyclin K (Cyclin K), enhancing antiproliferative effects on tumor cells. PPA-037 TFA is promising for research of cancers[1].

• UNSPSC:

  12352005

• Target:

  CDK

• Related Pathways:

  Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Purity:

  99.42

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  OC(C(F)(F)F)=O.C1(CNC2=CC(N[C@H]3CCNC3)=NC4=C(C5CC5)C=NN24)=CC=C(C6=CC=CC=N6)C=C1

• Molecular Formula:

  C27H28F3N7O2

• Molecular Weight:

  539.55

• References & Citations:

  [1]Edward AINSCOW, et al. Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use. WO2022263604A1. 2022-12-22

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK12